Journal
CURRENT OPINION IN MICROBIOLOGY
Volume 4, Issue 5, Pages 540-545Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/S1369-5274(00)00248-4
Keywords
-
Categories
Ask authors/readers for more resources
The therapeutic landscape for mycotic infections is shifting. New generation azoles that are active against clinically relevant, drug-resistant fungal pathogens have improved bioavailability, half-lives and safety profiles. Acylated cyclic peptide inhibitors of beta (1,3)glucan synthesis with origins as fungal metabolites provide an alternative and highly-selective mode of action, targeting cell-wall biogenesis in important pathogens such as Candida and Aspergillus species. The development, in each structural class, of compounds that have advanced to late-stage clinical trials is summarized in this review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available